maccura(SZ:300463)2025-10-24 09:05Financial Performance - The company's revenue for Q3 2025 was ¥532,849,978.83, a decrease of 20.32% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥3,060,863.16, down 96.16% year-on-year, while the net profit excluding non-recurring items was ¥1,250,879.71, a decline of 98.66%[5]. - Total operating revenue decreased to ¥1,607,884,075.22 from ¥1,947,615,476.64, representing a decline of approximately 17.4% year-over-year[23]. - Net profit for the period was ¥43,024,083.77, down from ¥283,096,995.04, indicating a decline of approximately 84.8% year-over-year[24]. - Basic earnings per share were ¥0.0050, down 96.15% compared to the same period last year[5]. - Basic earnings per share for the period was CNY 0.0606, down from CNY 0.4635 in the previous period[25]. - Diluted earnings per share for the period was CNY 0.0606, compared to CNY 0.4594 in the previous period[25]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥310,378,651.88, representing a decrease of 37.04% compared to the previous year[11]. - Investment cash flow for the year-to-date was -¥484,482,792.58, a decrease of 10.32% year-on-year, attributed to reduced investment in the Tianfu International Biological City IVD Industrial Park project[11]. - Cash inflow from financing activities was CNY 830,309,635.83, an increase of 43% from CNY 580,793,037.56 in the previous period[27]. - Net cash flow from investing activities was -CNY 484,482,792.58, slightly improved from -CNY 540,240,818.26 in the previous period[27]. - Total cash outflow from operating activities was CNY 1,681,369,859.76, down from CNY 1,811,099,189.49 in the previous period[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,988,985,705.04, showing a slight increase of 0.16% from the end of the previous year[5]. - Total liabilities rose to ¥1,609,600,676.96 from ¥1,552,644,190.08, an increase of about 3.7% year-over-year[21]. - The company's equity attributable to shareholders decreased to ¥6,326,115,358.60 from ¥6,369,056,728.78, a decline of approximately 0.7%[21]. - Cash and cash equivalents at the end of the period amount to RMB 674,786,812.33, slightly increasing from RMB 671,453,066.24 at the beginning[19]. - Cash and cash equivalents decreased to ¥3,412,441,963.83 from ¥3,639,623,036.94, a drop of about 6.2%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,893[13]. - The largest shareholder, Tang Yong, holds 11.26% of shares, totaling 68,062,301 shares, with 51,046,726 shares under lock-up[13]. - The company has a total of 120,621,001 restricted shares at the beginning of the period, with 7,762,787 shares released and 8,250 shares added, resulting in 112,866,464 restricted shares at the end[16]. - The company plans to reduce its registered capital by 7,802,966 shares, changing the total shares from 612,469,590 to 604,666,624[17]. - The company has transferred 51% equity of its subsidiary, Shandong Mike Biotechnology Co., Ltd., for a transaction price of RMB 17,412,879[17]. Operational Metrics - Accounts receivable decreased by 18.16% to ¥1,279,303,091.22 due to improved collection management[9]. - Accounts receivable decreased from RMB 1,563,178,437.53 to RMB 1,279,303,091.22 during the reporting period[19]. - Inventory increased from RMB 901,575,563.10 to RMB 931,047,217.76[19]. - The gross profit margin was negatively impacted by a 31.48% increase in taxes and surcharges due to increased deductible VAT[10]. - The company experienced a 223.26% rise in non-operating expenses, totaling ¥28,031,587.08, primarily due to tax payments and equipment write-offs[10]. Research and Development - Research and development expenses were ¥206,458,830.00, compared to ¥223,099,816.06 in the previous period, reflecting a decrease of about 7.4%[24]. Audit Status - The company’s financial report for the third quarter was not audited[29].